Research graph
References from The Cost of Uncertainty: Operational Consequences of Eliminating Routine DAT Screening. Local targets link to admitted publications; unresolved targets remain external evidence.
Clinical practice guideline revision: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation
10.1542/peds.2022-058859 · 2022 · External reference
AAP 2022 hyperbilirubinemia management calculator
2012 · External reference
Births in the United States
2024 · External reference
Impact of the 2022 AAP guidelines on neonatal hyperbilirubinemia admissions: a PHIS study
10.1542/hpeds.2024-008205 · 2025 · External reference
Incidence, etiology, and outcomes of hazardous hyperbilirubinemia in newborns
10.1542/peds.2014-0987 · 2014 · External reference
Bilirubin measurement and phototherapy use after the AAP 2022 newborn hyperbilirubinemia guideline
10.1542/peds.2023-063323 · 2024 · External reference
Serum albumin assessment in neonatal jaundice: impact on phototherapy decision-making
10.1542/hpeds.2024-007980 · 2025 · External reference
Importance of direct antiglobulin test (DAT) in cord blood: causes of DAT (+) in a cohort study
10.1016/j.pedneo.2014.11.005 · 2015 · External reference
